BACKGROUND: Synovial cell sarcoma is a rare soft tissue sarcoma. The purpose of this study was to investigate clinicopathologic factors and management on survival in primary synovial sarcoma of the head and neck. METHODS: We conducted a retrospective case series of medical records. Standard Kaplan-Meier survival analyses and accompanying log-rank tests were used. RESULTS: Twenty-eight patients were identified. All patients had surgery in attempt to remove the primary lesion. Nine patients received adjuvant radiation therapy, 2 received chemotherapy, and 14 received chemoradiation therapy postoperatively. Metastases on initial presentation and tumor size >4 cm decreased survival. No significant effect on overall survival or local tumor recurrence with histologic subtype, lymph node involvement at diagnosis, tumors >5 cm, or when comparing adjuvant therapy types. CONCLUSION: Although surgery remains the mainstay of treatment, our results do not suggest that adding chemotherapy to postoperative radiotherapy confers a survival or control benefit.
BACKGROUND: Synovial cell sarcoma is a rare soft tissue sarcoma. The purpose of this study was to investigate clinicopathologic factors and management on survival in primary synovial sarcoma of the head and neck. METHODS: We conducted a retrospective case series of medical records. Standard Kaplan-Meier survival analyses and accompanying log-rank tests were used. RESULTS: Twenty-eight patients were identified. All patients had surgery in attempt to remove the primary lesion. Nine patients received adjuvant radiation therapy, 2 received chemotherapy, and 14 received chemoradiation therapy postoperatively. Metastases on initial presentation and tumor size >4 cm decreased survival. No significant effect on overall survival or local tumor recurrence with histologic subtype, lymph node involvement at diagnosis, tumors >5 cm, or when comparing adjuvant therapy types. CONCLUSION: Although surgery remains the mainstay of treatment, our results do not suggest that adding chemotherapy to postoperative radiotherapy confers a survival or control benefit.
Authors: Adepitan A Owosho; Cherry L Estilo; Evan B Rosen; SaeHee K Yom; Joseph M Huryn; Cristina R Antonescu Journal: Oral Oncol Date: 2017-01-10 Impact factor: 5.337
Authors: Vancheswaran Gopalakrishnan; Behrang Amini; Michael J Wagner; Erica N Nowell; Alexander J Lazar; Patrick P Lin; Robert S Benjamin; Dejka M Araujo Journal: Sarcoma Date: 2017-06-05